Phase 2 is for dosage, Phase 3 for efficacy. They could apply for EUA at the 50% interim analysis, if overwhelming success is demonstrated, trial could stopped, because arm deserves treat, or trial could continue with EUA is granted. The key is a high N to demonstrate power. Let's keep our fingers crossed.